Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genetic Tech Spn Ads (GENE)

Genetic Tech Spn Ads (GENE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,191
  • Shares Outstanding, K 13,548
  • Annual Sales, $ 10 K
  • Annual Income, $ -4,100 K
  • 60-Month Beta 2.65
  • Price/Sales 10,606.15
  • Price/Cash Flow N/A
  • Price/Book 8.49
Trade GENE with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.33 +66.67%
on 12/29/20
8.18 -32.15%
on 01/21/21
+2.11 (+61.34%)
since 12/22/20
3-Month
2.77 +100.36%
on 11/10/20
8.18 -32.15%
on 01/21/21
+2.15 (+63.23%)
since 10/22/20
52-Week
1.41 +294.09%
on 03/23/20
10.30 -46.12%
on 07/15/20
+1.12 (+25.14%)
since 01/22/20

Most Recent Stories

More News
Genetic Technologies Announces $6.56 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with...

GENE : 5.55 (+1.28%)
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company"), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic...

GENE : 5.55 (+1.28%)
Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the 'Company'), announced today that they have entered into a three-year partnership agreement with mental health company,...

GENE : 5.55 (+1.28%)
Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, "Company") is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report...

GENE : 5.55 (+1.28%)
Genetic Technologies to Hold Investor Webinar and Q&A Session on November 19

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, "Company") is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company's recent...

GENE : 5.55 (+1.28%)
Genetic Technologies Provides Update on COVID-19 Risk Test

Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, "Company"), provides the following update to the market on the development of the Company's COVID-19 Risk Test.

GENE : 5.55 (+1.28%)
Genetic Technologies Provides Update on COVID-19 Disease Severity Test Development

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) ("Genetic Technologies" or the "Company") is developing a Polygenic Risk Score (PRS) test for COVID-19 which may enable...

GENE : 5.55 (+1.28%)
Genetic Technologies Announces US Sales Have Commenced via Online Health Platform

Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, "Company") is delighted to announce that initial sales of its GeneType for Breast Cancer Risk Assessment have now commenced...

GENE : 5.55 (+1.28%)
Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, is pleased to announce that it received notification from the Listing...

GENE : 5.55 (+1.28%)
Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company's...

GENE : 5.55 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across...

See More

Key Turning Points

3rd Resistance Point 6.20
2nd Resistance Point 5.90
1st Resistance Point 5.72
Last Price 5.55
1st Support Level 5.24
2nd Support Level 4.94
3rd Support Level 4.76

See More

52-Week High 10.30
Fibonacci 61.8% 6.90
Fibonacci 50% 5.85
Last Price 5.55
Fibonacci 38.2% 4.80
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar